6 research outputs found
Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population).
<p>Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population).</p
Week 52 glomerular filtration rate (MDRD) changes, by baseline rate and treatment (efficacy population).
<p>Week 52 glomerular filtration rate (MDRD) changes, by baseline rate and treatment (efficacy population).</p
Most common (≥5%) all-cause adverse events through Week 52 (safety population).
*<p>Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be less than the row total.</p><p>doi:10.1371/journal.pone.0054279.t003</p
Demographics and baseline characteristics (efficacy population) according to post-Week 24 treatment.
<p>doi:10.1371/journal.pone.0054279.t001</p